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INTRODUCTION
The diagnosis of HIV infection has played very
critical roles over the past two decades in detecting
and monitoring infection as well as patient
management. HIV infection is established by
detecting antibodies to the virus, viral antigens, viral
RNA/DNA, or by culture . To test for the viral
particle or the viral antigen is a difficult procedure.
The most common method used is serology for
antibody detection by ELISA or agglutination.
Positive results are then usually confirmed by
western blot (immunoblot) or further specific tests
such as competitive ELISA .
As technology evolved, screening, confirmatory and
HIV monitoring assays have greatly improved in
terms of quality and speed. Coupled with this
development is the unprecedented increase in the
number of test kits that are available for determining
HIV status. Test kits that are simple, instrument-free
simple/rapid tests are commercially available for
measuring ant ibodies by enzyme-linked
immunoassay (EIA). If performed properly, these
tests have a sensitivity and specificity exceeding 98
% . Moreover, they are also less expensive and do not
require high level of technological expertise to
perform or interpret and produce fewer
indeterminate results .
For small blood-collection centers and hospitals in
developing countries, screening tests are needed that
have the following specific characteristics; high







ambient temperatures, reasonable cost, and ease and
rapidity of performance .
Accurate and reliable results are essential when
testing HIV because the implications of false positive
or false negative results are serious and affect the
objectives of voluntary counseling and testing.
For the reasons stated above, we evaluated a variety
of commercial HIV test kits in order to identify
appropriate test kits for use in a developing country.
The evaluation was carried out using a panel of 92
sera obtained from clients who came for Voluntary
Testing and Counseling (VCT) between January and
March 2006, at the Special Treatment Clinic, (STC)
of the Jos University Teaching Hospital (JUTH), a
tertiary care center servicing about 19 states in north
central Nigeria and the federal capital territory.
This is a prospective, anonymous and unlinked study.
Four commercially available assay kits were
evaluated: SDbioline HIV-1/2 3.0 (Biotec
laboratories Ltd UK) Diaspot HIV 1/ 2(no
manufacturer or place of manufacture indicated) and
Determine™HIV 1/ 2 (Abbot Japan) and one ELISA
kit-DIALAB Elisa (Biorad, France). A Western blot
(QualiCode™ immunetics Inc, USA) kit was used as
the reference. All the kits were used within the
expiration dates.
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Accurate and reliable diagnosis of HIV plays a central role in any effective HIV intervention. We
decided to evaluate 4 commercial HIV test kits to determine their reliability for use in developing countries.
Serum samples obtained from clients accessing tertiary health services at the STI clinic, Jos
University Teaching Hospital were used to evaluate Sdbioline, Diaspot, Determine and DIALAB Elisa kits. A
Western blot was used as the reference kit.
kit gave 34 positive and 58 negative reactions and the positive sera were all confirmed
by Western blot while kit gave 27 false negative results, which was at variance with the reference kit
result. Other kits were with 5 false positive and kit, which gave one false
positive, and one false negative result.
We conclude that Determine, SDbioline and DIALAB Elisa kits are reliable for HIV antibody
testing in Nigeria and other developing countries.
HIV, Test Kits, Nigeria.
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assay kits used for HIV testing of patients in eight
laboratories of public and private health institutions
in Jos metropolis. The characteristics of the assay
kits are described in Table I.
After pre-test counseling, the cubital-fossa was
cleansed with 70% isopropyl alcohol and excess
alcohol was wiped off using sterile gauze. Five
milliliters of venous blood was obtained from the
cubital fossa into a sterile Z-10 plastic container
without anticoagulant and labeled with a number and
no personal identifiers or names were used. The
specimen was allowed to clot, and centrifuged at
1,500rpm for 10minutes in a clinical centrifuge
(Hettich, Rotanta, centrifuge, Germany), to separate
the serum.Aliquots of sera were extracted and stored
in cryo-vials at -20 C until tested. The test was
performed with each assay kit according to the
manufacturer's instructions.
Each S/R assay kit was evaluated with the entire
panel of 92 sera and their results recorded before
evaluating another assay kit. The evaluation was
conducted with the entire panel of 92 sera before any
repeat assay was carried out if an invalid result was
obtained. The results were read visually. The ELISA
evaluation was carried out for the entire panel of 92
sera as well as a positive and a negative control
samples. The ELISAresult was calculated according
to the manufacturer's instructions using the data
obtained with the ELISA Micro plate reader
(ELx800 universal BIO-TEK Instruments Inc.
USA). All positive specimens obtained, were
subjected to a Western blot assay. The results were
read visually. Band positions were compared to
those on the reference card developed using the HIV-
1/2 positive control serum.
The results of the evaluations were recorded in a
Specimen Collection and Laboratory Processing
Data Management
0
Laboratory worksheet. Any test that was repeated for
any reason was entered and reasons for the repeat
noted.
The Ethical committee of Jos University Teaching
Hospital approved this research protocol.
The results presented in Table 2 were obtained from
the evaluation of the three-simple/rapid assay kits,
one ELISA assay kit and a Western blot used to
confirm all the samples that reacted positive with all
the other test kits.
Of the 92 panel of sera
tested for HIV with this assay kit, 34 (37%) gave
positive reactions, while 58(63%) gave negative
Reactions. These results were confirmed by Western
blot.
Out of the 92 HIV tests carried
out with this kit, 7(7.6%) gave positive reactions,
while 85(92.4%) gave negative reactions. This result
does not agree with the reference kit result, which
gave 34 positive reactions.
HIV tests were also
carried out with this kit. The kit gave 39(42%)
positive reactions, while 53(58%) gave negative
reactions out of the 92 evaluations. This result again
does not agree with the reference kit value of 34
positive reactions. Five of the HIV antibody sero-
positive sera were not confirmed by the Western blot.
Of the 92 panel of sera tested
for HIV antibodies using this assay kit, 34(37%) gave
positive reactions, while 58(63%) gave negative
reactions. This kit gave one positive result and one
false negative result as indicated by the confirmation
test with Western blot. Also the false negative sera by




DETERMINE HIV 1/ 2:
DIASPOT HIV1/ 2:
SDBIOLINE HIV1/2 3.0:
DIALAB Elisa HIV ½:
Table 1: Characteristics of the Commercial HIV Antibody Assay Kits.















Sandwich Elisa Simple/Rapid Simple/Rapid Simple/Rapid Immunoblot
Recombinant Recombinant Recombinant Recombinant HIV-1 viral
Antigen /synth antigen antigen antigen/synth lystateprotein
-etic peptide -etic peptide /Recombinant
HIV-2 protein
flat wells Membrane Membrane Sample pad Immunoblot
membrane
96 40 30 100 24
100 10 5 50 10
100 10 10 15 220
Microplate Visual Visual Visual Visual
Reader
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determine a simple/rapid assay kit compared very
well with the reference kit. This finding is similar to
that reported for a rapid test by Constantine and
Ketema . The Dialab Elisa is a sandwich ELISA that
also showed excellent performance compared to the
reference test of HIV 1/2 antibody test. The high
performance by these assay kits may be due to the fact
that these two test kits utilize recombinant
antigen/synthetic peptide as the antigen type in
contrast to the other test kits (SDBioline and Diaspot)
that utilize only the recombinant antigen as their
antigen type. Interestingly also, Diaspot that showed
the widest discrepancy with the reference kit had no
manufacturer or place of manufacture indicated
anywhere on the kit.
In addition, adherence to the manufacturer's
specifications for transport and storage, which is
usually difficult to observe in resource-poor settings
such as obtained in Nigeria and many other
underdeveloped parts of the world, could contribute
to the poor performance of some of the kits such as the
Diaspot.
The Determine, SDbioline and DIALAB Elisa assay
kits performed the best in this evaluation and could be
confidently recommended for use in Nigeria.
However, by selecting combinations of these rapid
tests and ELISA, it should also be possible to use one
simple/rapid assay as screening test, and a subsequent
one as a confirmatory test. The two-simple/rapid test
could be used for screening in emergency settings and
resource- constrained areas . The first (screening) test
needs to be highly sensitive in order to provide for
reliable detection of antibodies in the serum
specimen .
It is to be noted that in areas of low disease
prevalence, it may be possible to use these assays as
screening tests to identify patients for presumptive
treatment .
We conclude that in this study; Determine, SDbioline
and DIALAB Elisa kits performed creditably well
and are therefore reliable for HIV antibody testing in
Nigeria and other developing countries.
We are grateful to the management of the Jos
University Teaching Hospital and the staff of STI
clinic Jos University Teaching Hospital for the
assistance.
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Table 2:
Determine 56 34 0 0
Diaspot 85 7 0 27
SDBioline 53 39 5 0
Dialab Elisa 56 34 1 1
N=92
An evaluation of commercial assay kits used for
detecting HIV 1 and 2 antibodies in Jos, Nigeria was
undertaken to determine their performance and
recommend assay kits that may be used for HIV
testing in Nigeria and other developing countries.
This study is important because it has been
established that early detection of HIV infection can
yield public health benefits by decreasing risk
behaviours that transmit HIV to uninfected persons.
Uninfected persons may also benefit from reliable
HIV testing since knowing their HIV status can
assist them in reducing or eliminating their risk-
taking behaviour. In addition, knowledge of one's
own HIV status and that of his or her partner may be
an important factor for preventing acquisition and
spread of HIV. The recently demonstrated benefits of
antiretroviral therapy have underscored the
influence of expanding HIV testing services to
facilitate early diagnosis and treatment of HIV
infected persons. The implication of accurate and
reliable results cannot be overemphasized in HIV
testing. But HIV testing kits of different
technologies and attractive claims by the
manufacturers are commercially available in spite of
restrictions by regulatory agencies such as Food and
Drug Administration (FDA), the National Agency
for Food and Drugs Administration and Control
(NAFDAC) and National AIDS/STDs Control
Programme (NASCP) .
The conventional ELISA method for detecting HIV
a number of shortcomings including: the assay
requires costly instruments and specialized reagents;
it is not rapid, it is not suitable for use in small or rural
health facilities; and it requires electricity which
is often unavailable or unreliable in most developing
countries.
The simple/rapid assays are more expensive to use,
but more suitable than the ELISAs in small clinics,
rural settings, emergency situations, blood banks
and where electricity is unreliable; they are easier to
perform, read visually, easy to interpret and yield
results within minutes.
Out of the four assay kits evaluated in this study,
Performance of the Commercial HIV
Antibody Assay Kits.
Assay kit No. No. No. false No. false
Nega Posi Posi Nega
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